📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
In 2023, Amicus Therapeutics completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Amicus Therapeutics has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Amicus Therapeutics’s data sources below and access millions more through our Disclosure Search.
No operational GHG emissions data disclosed for Amicus Therapeutics in 2023.
In 2023, the total Scope 1 emissions of Amicus Therapeutics were 0 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
In 2023, Amicus Therapeutics reported Scope 2 greenhouse gas (GHG) emissions of 0 tCOâ‚‚e without specifying the calculation method.a
In 2023, Amicus Therapeutics reported its Scope 2 emissions using an unspecified methodology.a